 CTA was introduced for medical use in the United States in 1952, and was subsequently introduced for use throughout Europe.It was the first estrogenic compound of the triphenylethylene series to be introduced.CTA was derived from estrobin (DBE), a derivative of the very weakly estrogenic compound triphenylethylene (TPE), which in turn was derived from structural modification of diethylstilbestrol (DES).